Elekta AB (publ) (OTCMKTS:EKTAY) Short Interest Update

Posted by Defense World Staff on Mar 29th, 2025

Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 400 shares, an increase of 300.0% from the February 28th total of 100 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 22,500 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Sanford C. Bernstein upgraded shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 29th.

Read Our Latest Report on EKTAY

Elekta AB (publ) Price Performance

Shares of OTCMKTS:EKTAY opened at $5.34 on Friday. The stock has a market capitalization of $2.05 billion, a P/E ratio of 21.35 and a beta of 1.25. The business has a 50-day moving average of $5.75 and a two-hundred day moving average of $5.93. Elekta AB has a fifty-two week low of $5.25 and a fifty-two week high of $8.24. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.05 and a quick ratio of 0.81.

Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) last released its earnings results on Friday, February 21st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. The company had revenue of $416.86 million for the quarter, compared to analyst estimates of $435.89 million. On average, equities research analysts predict that Elekta AB will post 0.36 EPS for the current fiscal year.

Elekta AB (publ) Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, March 27th. Shareholders of record on Friday, March 7th were given a $0.1072 dividend. The ex-dividend date of this dividend was Friday, March 7th. Elekta AB (publ)’s payout ratio is 44.00%.

Elekta AB (publ) Company Profile

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.